Maraviroc

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke

Maraviroc Efficacy for Hepatitis C

Maraviroc in Patients With Moderate and Severe COVID-19

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC

Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

Maraviroc and NeuroAIDS Pathogenesis

The Role of Home Packs of HIV PEPSE in High Risk Individuals

Safety and Efficacy of Maraviroc in Post-stroke Cognitive Impairment

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)